BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1411 related articles for article (PubMed ID: 32605588)

  • 21. Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines.
    Wu Q; Guo L; Jiang F; Li L; Li Z; Chen F
    J Cell Mol Med; 2015 Dec; 19(12):2874-87. PubMed ID: 26416600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
    Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
    Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Silico Identification of a BRCA1:miR-29:DNMT3 Axis Involved in the Control of Hormone Receptors in BRCA1-Associated Breast Cancers.
    Santarosa M; Baldazzi D; Armellin M; Maestro R
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential microRNA expression in breast cancer with different onset age.
    Tsai HP; Huang SF; Li CF; Chien HT; Chen SC
    PLoS One; 2018; 13(1):e0191195. PubMed ID: 29324832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
    Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening biomarkers of bladder cancer using combined miRNA and mRNA microarray analysis.
    Jin N; Jin X; Gu X; Na W; Zhang M; Zhao R
    Mol Med Rep; 2015 Aug; 12(2):3170-6. PubMed ID: 25955758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
    Giacomelli C; Jung J; Wachter A; Ibing S; Will R; Uhlmann S; Mannsperger H; Sahin Ö; Yarden Y; Beißbarth T; Korf U; Körner C; Wiemann S
    BMC Cancer; 2021 Dec; 21(1):1296. PubMed ID: 34863149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease.
    Qattan A
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and the Degree of Immune Cell Infiltration in Triple-negative Breast Cancer.
    Sato K; Miura K; Tamori S; Akimoto K
    Cancer Genomics Proteomics; 2024; 21(3):316-326. PubMed ID: 38670590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.
    Lehmann TP; Korski K; Gryczka R; Ibbs M; Thieleman A; Grodecka-Gazdecka S; Jagodziński PP
    Mol Med Rep; 2015 Sep; 12(3):4692-4702. PubMed ID: 26130254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
    Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
    Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
    Matamala N; Vargas MT; González-Cámpora R; Arias JI; Menéndez P; Andrés-León E; Yanowsky K; Llaneza-Folgueras A; Miñambres R; Martínez-Delgado B; Benítez J
    Oncotarget; 2016 Apr; 7(15):20068-79. PubMed ID: 26933805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
    Zhai Q; Li H; Sun L; Yuan Y; Wang X
    Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Race Disparities in the Contribution of miRNA Isoforms and tRNA-Derived Fragments to Triple-Negative Breast Cancer.
    Telonis AG; Rigoutsos I
    Cancer Res; 2018 Mar; 78(5):1140-1154. PubMed ID: 29229607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer.
    Turkistani S; Sugita BM; Fadda P; Marchi R; Afsari A; Naab T; Apprey V; Copeland RL; Campbell MC; Cavalli LR; Kanaan Y
    BMC Cancer; 2021 Jul; 21(1):861. PubMed ID: 34315420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systems biology approach and in vitro experiment indicated Rapamycin targets key cancer and cell cycle-related genes and miRNAs in triple-negative breast cancer cells.
    Tafti A; Shojaei S; Zali H; Karima S; Mohammadi-Yeganeh S; Mondanizadeh M
    Mol Carcinog; 2023 Dec; 62(12):1960-1973. PubMed ID: 37787375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.
    Fkih M'hamed I; Privat M; Trimeche M; Penault-Llorca F; Bignon YJ; Kenani A
    Pathol Oncol Res; 2017 Oct; 23(4):815-827. PubMed ID: 28101798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
    Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
    Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next‑generation sequencing.
    Wu H; Wang Q; Zhong H; Li L; Zhang Q; Huang Q; Yu Z
    Oncol Rep; 2020 Jan; 43(1):240-250. PubMed ID: 31746410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
    Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR
    J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 71.